[A trial of using Cefobid (cefoperazone) in treating infections of the skin and soft tissues]. 1994

V P Iakovlev, and L A Blatun, and M G Krutikov, and L S Puchkova, and L V Elagina, and G N Izotova

A clinical laboratory investigation of cefoperazon in the treatment of 27 patients with burn traumata and purulent necrotic wounds of the soft tissues of various genesis and localization was carried out. The clinical efficacy of the treatment was 75-86.6 per cent. 4 patients with extended purulent wounds of the soft tissues and bone affections were treated with cefoperazon and local application of gentacicol (a dosage form of gentamicin based on collagen with prolonged action) which provided the clinical effect in all the cases. 226 isolates from the wounds, urine, blood, sputum, pleural fluid and other substrates were tested and a rather high activity of cefoperazon against many strains of gram-positive and gram-negative organisms including Staphylococcus spp., Pseudomonas aeruginosa, Escherichia coli, Providencia sp. and Proteus spp. was revealed. The tolerance of the drug in all the cases was good.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002056 Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like. Burn
D002438 Cefoperazone Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections. Cefobid,Cefoperazon,Cefoperazone Sodium,Cefoperazone Sodium Salt,Céfobis,T-1551,T1551,Salt, Cefoperazone Sodium,Sodium Salt, Cefoperazone,Sodium, Cefoperazone,T 1551
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

V P Iakovlev, and L A Blatun, and M G Krutikov, and L S Puchkova, and L V Elagina, and G N Izotova
June 1988, Srpski arhiv za celokupno lekarstvo,
V P Iakovlev, and L A Blatun, and M G Krutikov, and L S Puchkova, and L V Elagina, and G N Izotova
June 1986, Orvosi hetilap,
V P Iakovlev, and L A Blatun, and M G Krutikov, and L S Puchkova, and L V Elagina, and G N Izotova
August 1984, The British journal of venereal diseases,
V P Iakovlev, and L A Blatun, and M G Krutikov, and L S Puchkova, and L V Elagina, and G N Izotova
January 2017, JAAPA : official journal of the American Academy of Physician Assistants,
V P Iakovlev, and L A Blatun, and M G Krutikov, and L S Puchkova, and L V Elagina, and G N Izotova
September 1986, Minerva chirurgica,
V P Iakovlev, and L A Blatun, and M G Krutikov, and L S Puchkova, and L V Elagina, and G N Izotova
November 1988, Bulletin de l'Academie nationale de medecine,
V P Iakovlev, and L A Blatun, and M G Krutikov, and L S Puchkova, and L V Elagina, and G N Izotova
July 1996, Revista clinica espanola,
V P Iakovlev, and L A Blatun, and M G Krutikov, and L S Puchkova, and L V Elagina, and G N Izotova
January 1996, The New England journal of medicine,
V P Iakovlev, and L A Blatun, and M G Krutikov, and L S Puchkova, and L V Elagina, and G N Izotova
May 2024, Intensive care medicine,
V P Iakovlev, and L A Blatun, and M G Krutikov, and L S Puchkova, and L V Elagina, and G N Izotova
October 1982, Cutis,
Copied contents to your clipboard!